| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Gene expression correlates of clinical prostate cancer behavior.
|
Cancer Cell
|
2002
|
16.27
|
|
2
|
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.
|
Proc Natl Acad Sci U S A
|
2006
|
6.90
|
|
3
|
Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
|
Cancer
|
2002
|
3.72
|
|
4
|
Bladder cancer.
|
J Natl Compr Canc Netw
|
2013
|
2.46
|
|
5
|
Radical retropubic prostatectomy and robotic-assisted laparoscopic prostatectomy: likelihood of positive surgical margin(s).
|
Urology
|
2010
|
2.31
|
|
6
|
Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer.
|
Clin Cancer Res
|
2005
|
1.68
|
|
7
|
Predictors of patient preferences and treatment choices for localized prostate cancer.
|
Cancer
|
2008
|
1.66
|
|
8
|
Management of the incidental renal mass.
|
Radiology
|
2008
|
1.66
|
|
9
|
Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
|
Cancer
|
2006
|
1.58
|
|
10
|
Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate.
|
J Clin Oncol
|
2002
|
1.47
|
|
11
|
Renal tumors: MR imaging-guided percutaneous cryotherapy--initial experience in 23 patients.
|
Radiology
|
2005
|
1.45
|
|
12
|
Primary retroperitoneal lymph node dissection in patients with clinical stage IS testis cancer.
|
J Urol
|
2009
|
1.44
|
|
13
|
New frontiers in nanotechnology for cancer treatment.
|
Urol Oncol
|
2008
|
1.42
|
|
14
|
Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer.
|
Cancer
|
2007
|
1.37
|
|
15
|
Development of an integrated prostate cancer research information system.
|
Clin Genitourin Cancer
|
2006
|
1.36
|
|
16
|
Bladder cancer.
|
J Natl Compr Canc Netw
|
2009
|
1.32
|
|
17
|
The zinc finger protein ras-responsive element binding protein-1 is a coregulator of the androgen receptor: implications for the role of the Ras pathway in enhancing androgenic signaling in prostate cancer.
|
Mol Endocrinol
|
2007
|
1.20
|
|
18
|
Evidence to support a continued stage migration and decrease in prostate cancer specific mortality.
|
J Urol
|
2006
|
1.19
|
|
19
|
Tumor detection by virtual cystoscopy with color mapping of bladder wall thickness.
|
J Urol
|
2002
|
1.16
|
|
20
|
Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era.
|
Urology
|
2002
|
1.16
|
|
21
|
A critical analysis of the actual role of minimally invasive surgery and active surveillance for kidney cancer.
|
Eur Urol
|
2009
|
1.13
|
|
22
|
Intertubular growth in pure seminomas: associations with poor prognostic parameters.
|
Hum Pathol
|
2005
|
1.10
|
|
23
|
Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.
|
Cancer
|
2012
|
1.07
|
|
24
|
Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen era.
|
Int J Radiat Oncol Biol Phys
|
2002
|
1.06
|
|
25
|
Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer.
|
Cancer
|
2006
|
1.04
|
|
26
|
Bladder cancer. Clinical guidelines in oncology.
|
J Natl Compr Canc Netw
|
2006
|
1.04
|
|
27
|
Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy.
|
Cancer
|
2003
|
0.97
|
|
28
|
Penile cancer: Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2013
|
0.97
|
|
29
|
Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate.
|
Urology
|
2003
|
0.95
|
|
30
|
Development of a "reverse capture" autoantibody microarray for studies of antigen-autoantibody profiling.
|
Proteomics
|
2006
|
0.95
|
|
31
|
Surgical apgar outcome score: perioperative risk assessment for radical cystectomy.
|
J Urol
|
2009
|
0.93
|
|
32
|
Blood-based biomarkers of aggressive prostate cancer.
|
PLoS One
|
2012
|
0.92
|
|
33
|
Bladder cancer. Clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2005
|
0.91
|
|
34
|
Unraveling androgen receptor interactomes by an array-based method: discovery of proto-oncoprotein c-Rel as a negative regulator of androgen receptor.
|
Exp Cell Res
|
2006
|
0.90
|
|
35
|
Morbidity of open retroperitoneal lymph node dissection for testicular cancer: contemporary perioperative data.
|
BJU Int
|
2009
|
0.89
|
|
36
|
Prostate carcinoma tissue proteomics for biomarker discovery.
|
Cancer
|
2003
|
0.89
|
|
37
|
PSA outcome following radical prostatectomy for patients with localized prostate cancer stratified by prostatectomy findings and the preoperative PSA level.
|
Urol Oncol
|
2005
|
0.88
|
|
38
|
Predictors of short postoperative prostate-specific antigen doubling time for patients diagnosed during PSA era.
|
Urology
|
2005
|
0.88
|
|
39
|
Lower prostate specific antigen outcome than expected following radical prostatectomy in patients with high grade prostate and a prostatic specific antigen level of 4 ng/ml. Or less.
|
J Urol
|
2002
|
0.87
|
|
40
|
Variations in surgeon volume and use of pelvic lymph node dissection with open and minimally invasive radical prostatectomy.
|
Urology
|
2008
|
0.86
|
|
41
|
Maximal tumor diameter and the risk of PSA failure in men with specimen-confined prostate cancer.
|
Urology
|
2005
|
0.86
|
|
42
|
Radical prostatectomy reigns supreme.
|
Oncology (Williston Park)
|
2009
|
0.85
|
|
43
|
Using PSA, biopsy Gleason score, clinical stage, and the percentage of positive biopsies to identify optimal candidates for prostate-only radiation therapy.
|
Int J Radiat Oncol Biol Phys
|
2002
|
0.85
|
|
44
|
Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen.
|
Clin Chim Acta
|
2011
|
0.83
|
|
45
|
A native antigen "reverse capture" microarray platform for autoantibody profiling of prostate cancer sera.
|
Proteomics Clin Appl
|
2007
|
0.82
|
|
46
|
Invasion of seminal vesicles by adenocarcinoma of the prostate: PSA outcome determined by preoperative and postoperative factors.
|
Urology
|
2004
|
0.81
|
|
47
|
Percentage of core lengths involved with prostate cancer: does it add to the percentage of positive prostate biopsies in predicting postoperative prostate-specific antigen outcome for men with intermediate-risk prostate cancer?
|
Urology
|
2002
|
0.81
|
|
48
|
Retroperitoneal lymph node dissection in patients with high risk testicular cancer.
|
J Urol
|
2009
|
0.80
|
|
49
|
Chromatofocusing fractionation and two-dimensional difference gel electrophoresis for low abundance serum proteins.
|
Proteomics
|
2005
|
0.78
|
|
50
|
Can the core length involved with prostate cancer identify clinically insignificant disease in low risk patients diagnosed on the basis of a single positive core?
|
Urol Oncol
|
2003
|
0.78
|
|
51
|
Predictive factor analysis as the basis for the clinical utility of percent positive prostate biopsies in patients with intermediate-risk prostate cancer.
|
Urology
|
2002
|
0.76
|
|
52
|
Radical prostatectomy for high-grade prostate cancer.
|
Urology
|
2006
|
0.76
|
|
53
|
Re: towards the definition of the best management and prognostic factors of teratoma with malignant transformation: a single-institution case series and new proposal.
|
J Urol
|
2012
|
0.76
|
|
54
|
MAGE-A4, a germ cell specific marker, is expressed differentially in testicular tumors.
|
J Urol
|
2002
|
0.76
|
|
55
|
Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry.
|
J Urol
|
2005
|
0.76
|
|
56
|
Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.
|
J Urol
|
2005
|
0.76
|
|
57
|
Re: First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.
|
J Urol
|
2012
|
0.75
|
|
58
|
Re: 18F-FDG PET/CT Impact on Testicular Tumours Clinical Management.
|
J Urol
|
2015
|
0.75
|
|
59
|
Re: Primary retroperitoneal lymph node dissection in low-stage testicular germ cell tumors: a detailed pathologic study with clinical outcome analysis with special emphasis on patients who did not receive adjuvant therapy.
|
J Urol
|
2014
|
0.75
|
|
60
|
Testicular function following chemotherapy.
|
J Urol
|
2002
|
0.75
|
|
61
|
Re: Incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma.
|
J Urol
|
2012
|
0.75
|
|
62
|
Re: First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG).
|
J Urol
|
2014
|
0.75
|
|
63
|
Re: Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group.
|
J Urol
|
2012
|
0.75
|
|
64
|
Re: Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular cancer survivors.
|
J Urol
|
2014
|
0.75
|
|
65
|
Re: presence of teratoma in orchiectomy specimen increases the need for postchemotherapy RPLND.
|
J Urol
|
2011
|
0.75
|
|
66
|
Re: Sequelae of treatment in long-term survivors of testis cancer.
|
J Urol
|
2012
|
0.75
|
|
67
|
Re: An alternative treatment regimen of advanced seminoma with carboplatin, etoposide, and bleomycin instead of cisplatin-based therapy.
|
J Urol
|
2013
|
0.75
|
|
68
|
Re: The PDGFRβ-AKT Pathway Contributes to CDDP-Acquired Resistance in Testicular Germ Cell Tumors.
|
J Urol
|
2015
|
0.75
|
|
69
|
Chromosome abnormalities of eighty-one pediatric germ cell tumors: sex-, age-, site,- and histopathology-related differences--a Children's Cancer Group Study.
|
J Urol
|
2002
|
0.75
|
|
70
|
OCT4 staining in testicular tumors. A sensitive and specific marker for seminoma and embryonal carcinoma.
|
J Urol
|
2005
|
0.75
|
|
71
|
Urological oncology: testis cancer.
|
J Urol
|
2010
|
0.75
|
|
72
|
Management preferences following radical inguinal orchidectomy for Stage 1 testicular seminoma in Australasia.
|
J Urol
|
2003
|
0.75
|
|
73
|
Re: Early experience with contrast-enhanced ultrasound in the diagnosis of testicular masses: a feasibility study.
|
J Urol
|
2012
|
0.75
|
|
74
|
Re: lymph node management in patients with paratesticular rhabdomyosarcoma: a population-based analysis.
|
J Urol
|
2014
|
0.75
|
|
75
|
Re: dynamic contrast-enhanced subtraction MRI for characterizing intratesticular mass lesions.
|
J Urol
|
2013
|
0.75
|
|
76
|
Re: patterns of management and surveillance imaging amongst medical oncologists in Australia for stage I testicular cancer.
|
J Urol
|
2014
|
0.75
|
|
77
|
Familial risk in testicular cancer as a clue to a heritable and environmental aetiology.
|
J Urol
|
2005
|
0.75
|
|
78
|
Re: Variants in or near KITLG, BAK1, DMRT1, and TERT-CLPTM1L predispose to familial testicular germ cell tumour.
|
J Urol
|
2012
|
0.75
|
|
79
|
Re: Role of Surgical Resection for Refractory Germ Cell Tumors.
|
J Urol
|
2016
|
0.75
|
|
80
|
Re: The clinical features and management of testicular germ cell tumours in patients aged 60 years and older.
|
J Urol
|
2012
|
0.75
|
|
81
|
Is there an increased incidence of contralateral testicular cancer in patients with intratesticular microlithiasis?
|
J Urol
|
2003
|
0.75
|
|
82
|
Re: Global trends in testicular cancer incidence and mortality.
|
J Urol
|
2012
|
0.75
|
|
83
|
Re: Trends in Testicular Cancer Survival: A Large Population-Based Analysis.
|
J Urol
|
2015
|
0.75
|
|
84
|
Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group.
|
J Urol
|
2003
|
0.75
|
|
85
|
Re: Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe.
|
J Urol
|
2012
|
0.75
|
|
86
|
Re: Barriers to the implementation of surveillance for stage I testicular seminoma.
|
J Urol
|
2013
|
0.75
|
|
87
|
Low p21Waf1/Cip1 Protein Level Sensitizes Testicular Germ Cell Tumor Cells to Fas-Mediated Apoptosis.
|
J Urol
|
2005
|
0.75
|
|
88
|
Testicular implants and patient satisfaction: a questionnaire-based study of men after orchidectomy for testicular cancer.
|
J Urol
|
2002
|
0.75
|
|
89
|
Malignant germ cell tumors: clinical characteristics, treatment, and outcome. A report from the Study Group for Pediatric Solid Malignant Tumors in the Kyushu area, Japan.
|
J Urol
|
2003
|
0.75
|
|
90
|
Re: real-time tissue elastography for testicular lesion assessment.
|
J Urol
|
2013
|
0.75
|
|
91
|
Re: Testicular cancer incidence to rise by 25% in Europe? Model-based predictions in 40 countries using population-based registry data.
|
J Urol
|
2014
|
0.75
|
|
92
|
Re: Management Trends in Stage I Testicular Seminoma: Impact of Race, Insurance Status, and Treatment Facility.
|
J Urol
|
2015
|
0.75
|
|
93
|
Re: CMTM3 Inhibits Human Testicular Cancer Cell Growth through Inducing Cell-Cycle Arrest and Apoptosis.
|
J Urol
|
2015
|
0.75
|
|
94
|
Re: Early development of the metabolic syndrome after chemotherapy for testicular cancer.
|
J Urol
|
2014
|
0.75
|
|
95
|
Somatic mutations of KIT in familial testicular germ cell tumours.
|
J Urol
|
2005
|
0.75
|
|
96
|
Re: Craniocaudal Retroperitoneal Node Length as a Risk Factor for Relapse from Clinical Stage I Testicular Germ Cell Tumor.
|
J Urol
|
2015
|
0.75
|
|
97
|
Re: Testicular-Sparing Surgery for Bilateral or Monorchide Testicular Tumours: A Multicenter Study of Long-Term Oncological and Functional Results.
|
J Urol
|
2015
|
0.75
|
|
98
|
Late recurrence in 1263 men with testicular germ cell tumors. Multivariate analysis of risk factors and implications for management.
|
J Urol
|
2003
|
0.75
|
|
99
|
Prospective study of carboplatin-based chemotherapy for pediatric germ cell tumors.
|
J Urol
|
2003
|
0.75
|
|
100
|
Editorial: testis cancer--paradigm for reduction in morbidity without sacrifice of efficacy.
|
J Urol
|
2002
|
0.75
|
|
101
|
Re: A meta-analysis of the risk of boys with isolated cryptorchidism developing testicular cancer in later life.
|
J Urol
|
2013
|
0.75
|
|
102
|
Re: testicular cancer in Europe and the USA: survival still rising among older patients.
|
J Urol
|
2014
|
0.75
|
|
103
|
Re: second malignant neoplasms in testicular cancer survivors.
|
J Urol
|
2012
|
0.75
|
|
104
|
Re: Phenotypic Characterisation of Immune Cell Infiltrates in Testicular Germ Cell Neoplasia.
|
J Urol
|
2015
|
0.75
|
|
105
|
Urological oncology: testis cancer.
|
J Urol
|
2011
|
0.75
|
|
106
|
Re: Organ preservation technique without ischemia in patients with testicular tumor.
|
J Urol
|
2015
|
0.75
|
|
107
|
Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK/ERK activation.
|
J Urol
|
2005
|
0.75
|
|
108
|
Establishment of a testicular carcinoma cell line producing alpha-fetoprotein.
|
J Urol
|
2002
|
0.75
|
|
109
|
Re: Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish Norwegian testicular cancer study group.
|
J Urol
|
2011
|
0.75
|
|
110
|
Re: genomic characterization of testis cancer: association of alterations with outcome of clinical stage 1 mixed germ cell nonseminomatous germ cell tumor of the testis.
|
J Urol
|
2013
|
0.75
|
|
111
|
Re: Public perceptions of the harms and benefits of testicular cancer education: a qualitative study.
|
J Urol
|
2011
|
0.75
|
|
112
|
Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis.
|
J Urol
|
2003
|
0.75
|
|
113
|
Re: tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors.
|
J Urol
|
2013
|
0.75
|
|
114
|
Re: Pathological findings after primary chemotherapy in patients undergoing simultaneous orchidectomy and retroperitoneal lymph node dissection for advanced germ cell tumours.
|
J Urol
|
2013
|
0.75
|
|
115
|
Re: clinical analysis of management of pediatric testicular germ cell tumors.
|
J Urol
|
2012
|
0.75
|
|
116
|
Re: Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer.
|
J Urol
|
2013
|
0.75
|
|
117
|
Preclinical and clinical activity of sunitinib in patients with Cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian urologic oncology group/German testicular cancer study group cooperative study.
|
J Urol
|
2012
|
0.75
|
|
118
|
Bilateral testicular germ cell tumors: twenty-year experience at M. D. Anderson Cancer Center.
|
J Urol
|
2003
|
0.75
|
|
119
|
Re: presence of teratoma in orchiectomy specimen increases the need for postchemotherapy RPLND.
|
J Urol
|
2012
|
0.75
|
|
120
|
Re: Best practices recommendations in the application of immunohistochemistry in testicular tumors: report from the International Society of Urological Pathology Consensus Conference.
|
J Urol
|
2015
|
0.75
|
|
121
|
Role of P53 and MDM2 in treatment response of human germ cell tumors.
|
J Urol
|
2003
|
0.75
|
|
122
|
Re: Circulating Tumor Cells in Patients with Testicular Germ Cell Tumors.
|
J Urol
|
2016
|
0.75
|
|
123
|
Introduction: International consultation on urologic diseases: testicular cancer: Societe Internationale d'Urologie/International Consultation on Urologic Diseases Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009.
|
Urology
|
2011
|
0.75
|
|
124
|
Re: Predictors of Sperm Recovery after Cryopreservation in Testicular Cancer.
|
J Urol
|
2017
|
0.75
|
|
125
|
Re: Radiation Exposure from Diagnostic Imaging in Young Patients with Testicular Cancer.
|
J Urol
|
2016
|
0.75
|
|
126
|
Re: Single-Nucleotide Polymorphism in the 5-α-Reductase Gene (SRD5A2) is Associated with Increased Prevalence of Metabolic Syndrome in Chemotherapy-Treated Testicular Cancer Survivors.
|
J Urol
|
2016
|
0.75
|
|
127
|
By the way, doctor. Ultrasound treatment for Peyronie's disease? I have Peyronie's disease. Nothing seems to help. But I've heard about a new treatment that involves some kind of ultrasound. What do you think?
|
Harv Health Lett
|
2002
|
0.75
|
|
128
|
Neuroepithelial tumor arising in a testicular teratoma with retroperitoneal metastasis.
|
J Clin Oncol
|
2012
|
0.75
|
|
129
|
Re: Genetic Determinants of Cisplatin Resistance in Patients with Advanced Germ Cell Tumors.
|
J Urol
|
2017
|
0.75
|
|
130
|
Re: Radiomics Allows for Detection of Benign and Malignant Histopathology in Patients with Metastatic Testicular Germ Cell Tumors prior to Post-Chemotherapy Retroperitoneal Lymph Node Dissection.
|
J Urol
|
2020
|
0.75
|
|
131
|
Urological Oncology: Testis Cancer and Advances in Oncologic Therapy.
|
J Urol
|
2022
|
0.75
|
|
132
|
Re: Outcome of Men with Relapse after Adjuvant Carboplatin for Clinical Stage I Seminoma.
|
J Urol
|
2017
|
0.75
|
|
133
|
Re: Changes in Adjuvant Therapy Utilization in Stage I Seminoma: Are they Enough to Prevent Overtreatment?
|
J Urol
|
2015
|
0.75
|
|
134
|
Re: Late Relapses in Stage I Testicular Cancer Patients on Surveillance.
|
J Urol
|
2016
|
0.75
|
|
135
|
Re: Surveillance after Initial Surgery for Stage I Pediatric and Adolescent Boys with Malignant Testicular Germ Cell Tumors: Report from the Children's Oncology Group.
|
J Urol
|
2016
|
0.75
|
|
136
|
Re: The Role of Testis-Sparing Surgery in Children and Adolescents with Testicular Tumors.
|
J Urol
|
2016
|
0.75
|
|
137
|
Gene expression profiling of early- and late-relapse nonseminomatous germ cell tumor and primitive neuroectodermal tumor of the testis.
|
J Urol
|
2005
|
0.75
|
|
138
|
Re: Testicular Seminoma Clinical Stage 1: Treatment Outcome on a Routine Care Level.
|
J Urol
|
2017
|
0.75
|
|
139
|
Re: Testicular Microlithiasis Imaging and Follow-up: Guidelines of the ESUR Scrotal Imaging Subcommittee.
|
J Urol
|
2016
|
0.75
|
|
140
|
Re: Expression of microRNAs of C19MC in Different Histological Types of Testicular Germ Cell Tumour.
|
J Urol
|
2016
|
0.75
|
|
141
|
The management of nonseminomatous testicular cancer.
|
ScientificWorldJournal
|
2004
|
0.75
|
|
142
|
Re: The World Health Organization 2016 Classification of Testicular Germ Cell Tumours: A Review and Update from the International Society of Urological Pathology Testis Consultation Panel.
|
J Urol
|
2017
|
0.75
|
|
143
|
Re: Is it Safe to Insert a Testicular Prosthesis at the Time of Radical Orchidectomy for Testis Cancer: An Audit of 904 Men Undergoing Radical Orchidectomy.
|
J Urol
|
2016
|
0.75
|
|
144
|
Re: Cardiovascular Disease Mortality after Chemotherapy or Surgery for Testicular Nonseminoma: A Population-Based Study.
|
J Urol
|
2016
|
0.75
|
|
145
|
Re: Spermatogenesis in Tumor-Bearing Testes in Germ Cell Testicular Cancer Patients.
|
J Urol
|
2017
|
0.75
|
|
146
|
Re: Second Malignant Neoplasms and Cause of Death in Patients with Germ Cell Cancer: A Danish Nationwide Cohort Study.
|
J Urol
|
2017
|
0.75
|
|
147
|
By the way, doctor. I have been taking Avodart for my BPH, along with Flomax, but finasteride may be less expensive. Should I switch?
|
Harv Health Lett
|
2008
|
0.75
|
|
148
|
Re: Conditional Survival of Patients with Metastatic Testicular Germ Cell Tumors Treated with First-Line Curative Therapy.
|
J Urol
|
2016
|
0.75
|
|
149
|
Solitary adrenal metastatic lesion in a patient with a history of prostate cancer.
|
Clin Genitourin Cancer
|
2009
|
0.75
|
|
150
|
Re: Patterns of Relapse in Patients with Clinical Stage I Testicular Cancer Managed with Active Surveillance.
|
J Urol
|
2016
|
0.75
|
|
151
|
Urological oncology: testis cancer.
|
J Urol
|
2011
|
0.75
|
|
152
|
Re: Cardiovascular Disease Mortality after Chemotherapy or Surgery for Testicular Nonseminoma: A Population-Based Study.
|
J Urol
|
2016
|
0.75
|
|
153
|
Re: Interim (18)F-Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Response to Cisplatin, Etoposide, and Bleomycin Chemotherapy for Metastatic Seminoma: Clinical Value and Future Directions.
|
J Urol
|
2017
|
0.75
|
|
154
|
Primary vs. post-chemotherapy retroperitoneal lymph node dissection (RPLND) in patients with presence of teratoma at orchiectomy.
|
Urol Oncol
|
2010
|
0.75
|
|
155
|
Urological Oncology: Testis Cancer and Advances in Oncologic Therapy.
|
J Urol
|
2021
|
0.75
|